Money
Filter News
Found 65,571 articles
-
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
-
Foghorn Booms onto Nasdaq with $120M IPO
10/23/2020
Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece. -
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
-
Canada's Prime Minister, Justin Trudeau, Announced Today Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19
10/23/2020
Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine
-
Entos Pharmaceuticals Awarded funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine
10/23/2020
Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its breakthrough proprietary Fusogenix drug delivery platform, is pleased to announce it is receiving advisory services and funding of up to $5M from the National Research Council of Canada Industrial Research Assistance Program
-
First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
10/23/2020
INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treatedwith a platinum-based therapy and PD-(L)1 inhibitor
-
HFC Raises Over $325K and Connects Over 2000 Supporters for Alzheimer's Awareness During First Virtual Game Show, Hosted by Seth Rogen
10/23/2020
National Alzheimer's Nonprofit Takes Annual Fundraising Virtual With Celebrity-Hosted, 70s-Themed Game Show Featuring Elizabeth Banks, Anna Faris, Jim Gaffigan, Billy Eichner and Craig Robinson.
-
Roche and Atea Pharmaceuticals are partnering to develop, manufacture and distribute AT-527, Atea’s experimental antiviral drug against COVID-19.
-
The new fund, RA Capital Nexus Fund II, will serve as a companion fund to RA’s Nexus I fund, which closed last year with approximately $300 million in capital.
-
It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.
-
Biopharma Money on the Move: October 15-21
10/22/2020
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
Vapotherm Announces Closing of Debt Refinancing
10/22/2020
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it has entered into a loan and security agreement with CIBC Innovation Banking that provides the Company with up to $52 million in debt financing through a combination of a term loan facility and a revolving credit facility
-
Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections
10/22/2020
Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.
-
Xtant Medical Announces Record Date and Other Key Dates for Proposed $15 Million Rights Offering
10/22/2020
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has set November 5, 2020 as the record date for its previously-announced proposed rights offering of up to $15 million of shares of its common stock and the expected subscription period.
-
Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain CancerProceeds to fund STELLAR study and additional clinical studies in patients with malignant gliomas
10/22/2020
Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that that it has closed an expansion of its Series A financing. As part of this expanded financing, Abingworth LLP has joined the existing Series A investors led by Longitude Capital, H.I.G. BioVentures and Adams Street Partners. In conjunction with the financing, Kur
-
Allonnia Launches from Ginkgo Bioworks' Ferment Consortium with $40M Series A to Address Critical Problems in Waste Remediation with Synthetic Biology, Appoints Nicole Richards as CEO
10/22/2020
Allonnia LLC, a bioremediation company, launched today with $40 million in Series A funding to find new answers to the growing challenge of waste management.
-
FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities
10/22/2020
EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) in response to a Broad Agency Announcement (BAA), FDA BAA-20-00123.
-
Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
10/22/2020
Grants Will Be Administered through the MECTIZAN® Donation Program and Will Support Precautionary Measures Required to Prevent the Spread of SARS-CoV-2 During Mass Drug Administration Programs for These Two Diseases KENILWORTH, N.J.--( BUSINESS WIRE )-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN® Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO)
-
Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease
10/22/2020
Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease -- Lead clinical asset AZR-MD-001 for Meibomian gland dysfunction to advance through registration study -- Meibomian gland dysfunction is the leading cause of Dry Eye Disease, a condition known to affect more than 30 million adults in the United States alone
-
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
10/22/2020
AavantiBio will pursue a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease characterized by cardiac and central nervous system dysfunction Bo Cumbo, most recently Sarepta’s Chief Commercial Officer and Executive Vice President, appointed Chief Executive Officer and President of AavantiBio Co-founded by pioneering gene therapy researchers Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D.,